Cover Image

Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Notice
This publication has been discontinued on July 3, 2013.

Abstract

Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Pain Therapeutics market. The report identifies the key trends shaping and driving the global Acute Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Pain Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Pain Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Acute Pain Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Pain Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Acute Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Acute Pain Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Pain Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Acute Pain Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Acute Pain Therapeutics - Introduction 7

  • 2.1 Disease Overview 7
  • 2.2 Epidemiology 8
  • 2.3 Etiology 11
  • 2.4 Pathophysiology 11
  • 2.5 Symptoms 13
  • 2.6 Diagnosis 14
    • 2.6.1 Unidimensional Pain Intensity Scales 14
    • 2.6.2 Multidimensional Pain Scales 16
    • 2.6.3 Commonly Used Diagnosis Tests 16
  • 2.7 Treatment and Management Options 16
    • 2.7.1 Pharmacologic Therapy 16
    • 2.7.2 Intervention/Surgical Procedures 17
    • 2.7.3 Non-Pharmacologic Approaches 17
  • 2.8 Referral Pathway 19
  • 2.9 GlobalData Pipeline Report Guidance 20

3 Acute Pain Therapeutics - Market Characterization 21

  • 3.1 Acute Pain Therapeutics Market Size (2006-2011) - Global 21
  • 3.2 Acute Pain Therapeutics Market Forecast (2011-2019) - Global 23
  • 3.3 Acute Pain Therapeutics Market Size (2006-2011) - The US 24
  • 3.4 Acute Pain Therapeutics Market Forecast (2011- 2019) - The US 25
  • 3.5 Acute Pain Therapeutics Market Size (2006-2011) - France 26
  • 3.6 Acute Pain Therapeutics Market Forecast (2011-2019) - France 27
  • 3.7 Acute Pain Therapeutics Market Size (2006-2011) - Germany 28
  • 3.8 Acute Pain Therapeutics Market Forecast (2011-2019) - Germany 29
  • 3.9 Acute Pain Therapeutics Market Size (2006-2011) - Italy 30
  • 3.10 Acute Pain Therapeutics Market Forecast (2011-2019) - Italy 31
  • 3.11 Acute Pain Therapeutics Market Size (2006-2011) - Spain 32
  • 3.12 Acute Pain Therapeutics Market Forecast (2011-2019) - Spain 33
  • 3.13 Acute Pain Therapeutics Market Size (2006-2011) - The UK 34
  • 3.14 Acute Pain Therapeutics Market Forecast (2011-2019) - The UK 35
  • 3.15 Acute Pain Therapeutics Market Size (2006-2011) - Japan 36
  • 3.16 Acute Pain Therapeutics Market Forecast (2011-2019) - Japan 37
  • 3.17 Drivers and Barriers for the Acute Pain Therapeutics Market 38
    • 3.17.1 Drivers for the Acute Pain Therapeutics Market 38
    • 3.17.2 Barriers for the Acute Pain Therapeutics Market 38
  • 3.18 Opportunity and Unmet Need 38
  • 3.19 Key Takeaway 40

4 Acute Pain Therapeutics - Competitive Assessment 41

  • 4.1 Overview 41
  • 4.2 Strategic Competitor Assessment 41
  • 4.3 Product Profiles for the Major Marketed Products in the Acute Pain Therapeutics Market 42
    • 4.3.1 Celebrex (celecoxib) 42
    • 4.3.2 DepoDur (morphine sulfate extended-release liposome injection) 43
    • 4.3.3 Ofirmev (acetaminophen injection) 45
    • 4.3.4 Oxecta (oxycodone hydrochloride Tablet) 46
    • 4.3.5 Nucynta (tapentadol) 47
    • 4.3.6 Dilaudid (hydromorphone hydrochloride) 49
    • 4.3.7 Sprix (ketorolac tromethamine) Nasal Spray 50
    • 4.3.8 Zipsor (diclofenac potassium) 51
    • 4.3.9 Flector Patch (diclofenac epolamine) 52
    • 4.3.10 Vicoprofen (hydrocodone bitartrate 7.5mg and ibuprofen 200mg) 54
  • 4.4 Key Takeaway 56

5 Acute Pain Therapeutics - Pipeline Assessment 57

  • 5.1 Overview 57
  • 5.2 Strategic Pipeline Assessment 57
  • 5.3 Acute Pain Therapeutics Pipeline - Pipeline by Phases of Development 58
    • 5.3.1 Acute Pain Therapeutics - Filed Pipeline 58
    • 5.3.2 Acute Pain Therapeutics - Phase III Pipeline 59
    • 5.3.3 Acute Pain Therapeutics - Phase II Pipeline 59
    • 5.3.4 Acute Pain Therapeutics - Phase I Pipeline 60
    • 5.3.5 Acute Pain Therapeutics - IND Filed Pipeline 60
    • 5.3.6 Acute Pain Therapeutics - Pre-clinical Pipeline 60
    • 5.3.7 Technology Trends Analytic Framework 61
  • 5.4 Acute Pain Therapeutics Market - Pipeline by Mechanism of Action 63
  • 5.5 Acute Pain Therapeutics - Promising Drugs under Clinical Development 64
  • 5.6 Molecule Profiles for Promising Drugs under Clinical Development 64
    • 5.6.1 MoxDuo IR (morphine and oxycodone) 64
    • 5.6.2 Dyloject (diclofenac sodium Fast-push Intravenous Bolus Injection) 65
    • 5.6.3 Ketotransdel (ketoprofen 10% Cream) 66
    • 5.6.4 MRX-7EAT (etodolac + lidocaine Topical Patch) 67
  • 5.7 Key Takeaway 67

6 Acute Pain Therapeutics - Clinical Trials Mapping 68

  • 6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 68
  • 6.2 Clinical Trials by Phase 69
  • 6.3 Clinical Trials by Trial Status 70
  • 6.4 Prominent Sponsors 71
  • 6.5 Top Companies Participating in Acute Pain Therapeutics Clinical Trials 73

7 Acute Pain Therapeutics - Strategic Assessment 74

  • 7.1 Key Events Impacting the Future Market 74
  • 7.2 Acute Pain Therapeutics: Implications for Future Market Competition 74

8 Acute Pain Therapeutics - Future Players 76

  • 8.1 Introduction 76
  • 8.2 Company Profiles 77
    • 8.2.1 Grunenthal 77
    • 8.2.2 QRxPharma 77
    • 8.2.3 Iroko Pharma 78
    • 8.2.4 Hospira 78
    • 8.2.5 Transdel Pharma 78
    • 8.2.6 MEDRx Co. 79

9 Acute Pain Therapeutics - Appendix 80

  • 9.1 Definitions 80
  • 9.2 Acronyms 80
  • 9.3 Bibliography 81
  • 9.4 Research Methodology 82
    • 9.4.1 Coverage 83
    • 9.4.2 Secondary Research 83
    • 9.4.3 Forecasting 83
    • 9.4.4 Primary Research 86
    • 9.4.5 Expert Panel Validation 87
  • 9.5 Contact Us 87
  • 9.6 Disclaimer 87

List of Tables

1.1 List of Tables

  • Table 1: Between Acute Pain and Chronic Pain 8
  • Table 2: Incidence Pool of Acute Pain in Seven Major Markets 8
  • Table 3: Number of Listed Procedures for Discharges from Short-Stay Hospitals, by Age and Procedure Category in the US from 2006 - 2009 9
  • Table 4: Symptoms Associated with Pain 13
  • Table 5: Initial Pain Assessment Guidelines 14
  • Table 6: Acute Pain Therapeutics Market, Global, Revenue ($m), 2006-2011 22
  • Table 7: Acute Pain Therapeutics Market, Global, Forecast ($m), 2011-2019 23
  • Table 8: Acute Pain Therapeutics Market, The US, Revenue ($m), 2006-2011 24
  • Table 9: Acute Pain Therapeutics Market, The US, Forecasts ($m), 2011-2019 25
  • Table 10: Acute Pain Therapeutics Market, France, Revenue ($m), 2006-2011 26
  • Table 11: Acute Pain Therapeutics Market, France, Forecasts ($m), 2011-2019 27
  • Table 12: Acute Pain Therapeutics Market, Germany, Revenue ($m), 2006-2011 28
  • Table 13: Acute Pain Therapeutics Market, Germany, Forecasts ($m), 2011-2019 29
  • Table 14: Acute Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011 30
  • Table 15: Acute Pain Therapeutics Market, Italy, Forecasts ($m), 2011-2019 31
  • Table 16: Acute Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011 32
  • Table 17: Acute Pain Therapeutics Market, Spain, Forecasts ($m), 2011-2019 33
  • Table 18: Acute Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011 34
  • Table 19: Acute Pain Therapeutics Market, The UK, Forecasts ($m), 2011-2019 35
  • Table 20: Acute Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011 36
  • Table 21: Acute Pain Therapeutics Market, Japan, Forecasts ($m), 2011-2019 37
  • Table 22: Adverse Drug Reactions of Celebrex in the Analgesia and Dysmenorrhea Clinical Trials 43
  • Table 23: Adverse Drug Reactions of DepoDur 44
  • Table 24: Adverse Drug Reactions Reported ≥3% in Adult Patients Treated with Either Ofirmev or Placebo* 46
  • Table 25: Adverse Drug Reactions Reported in Less than 3% of Oxecta-treated Patients 47
  • Table 26: Treatment Emergent Adverse Drug Reactions of Nucynta* 48
  • Table 27: Adverse Drug Reactions at a rate of ≥2% in Post-operative Acute Pain Patients Treated with Sprix 50
  • Table 28: Adverse Drug Reactions with Incidence ≥1% of Zipsor Treated Patients* 52
  • Table 29: Adverse Events in ≥1% of Patients treated with Flector Patch or Placebo Patcha 53
  • Table 30: Adverse Drug Reactions of Vicoprofen 55
  • Table 31: Acute Pain Therapeutics, Filed Pipeline, 2012 58
  • Table 32: Acute Pain Therapeutics, Phase III Pipeline, 2012 59
  • Table 33: Acute Pain Therapeutics, Phase II Pipeline, 2012 59
  • Table 34: Acute Pain Therapeutics, Phase I Pipeline, 2012 60
  • Table 35: Acute Pain Therapeutics, IND Filed Pipeline, 2012 60
  • Table 36: Acute Pain Therapeutics, Pre-clinical Pipeline, 2012 60
  • Table 37: Acute Pain Therapeutics, Most Promising Drugs Under Clinical Development, 2012 64
  • Table 38: Treatment-Emergent Adverse Events of Dyloject 65
  • Table 39: Acute Pain Therapeutics Market, Clinical Trials by Country, 2012 68
  • Table 40: Acute Pain Therapeutics Market Therapeutics, Clinical Trials by Phase, 2012 69
  • Table 41: Acute Pain Therapeutics, Clinical Trials by Status, 2012 70
  • Table 42: Acute Pain Therapeutics, Prominent Sponsors, 2012 72
  • Table 43: Acute Pain Therapeutics, Top Companies Participating in Acute Pain Therapeutics Clinical Trials, 2012 73
  • Table 44: Grunenthal, Acute Pain Pipeline Products, 2012 77
  • Table 45: QRxPharma, Acute Pain Pipeline Products, 2012 77
  • Table 46: Iroko Pharma, Acute Pain Pipeline Products, 2012 78
  • Table 47: Hospira, Acute Pain Pipeline Products, 2012 78
  • Table 48: Transdel Pharma, Acute Pain Pipeline Products, 2012 79
  • Table 49: MEDRx Co, Acute Pain Pipeline Products, 2012 79

List of Figures

1.2 List of Figures

  • Figure 1: Classification of Pain 7
  • Figure 2: Key Opinion Leaders Insights, Incidence of Acute Pain in the US and the UK 11
  • Figure 3: Nociceptive Pain Pathway 12
  • Figure 4: Pain Pathway and Interventions that Modulate Pain Activity at Each Point 13
  • Figure 5: Pain Measurement Scale - NRS 14
  • Figure 6: Pain Measurement Scale - VAS 15
  • Figure 7: Pain Measurement Scale - FRS 15
  • Figure 8: KOL Insights, Treatment of Acute Pain in the US and the UK 18
  • Figure 9: Acute Pain Patient Referral Pathway 19
  • Figure 10: KOL Insights, Referral Pathway for Acute Pain in the US and the UK 19
  • Figure 11: Acute Pain Therapeutics Market, Global, Revenue ($m), 2006-2011 22
  • Figure 12: Acute Pain Therapeutics Market, Global, Forecast ($m), 2011-2019 23
  • Figure 13: Acute Pain Therapeutics Market, The US, Revenue ($m), 2006-2011 24
  • Figure 14: Acute Pain Therapeutics Market, The US, Forecast ($m), 2011-2019 25
  • Figure 15: Acute Pain Therapeutics Market, France, Revenue ($m), 2006-2011 26
  • Figure 16: Acute Pain Therapeutics Market, France, Forecast ($m), 2011-2019 27
  • Figure 17: Acute Pain Therapeutics Market, Germany, Revenue ($m), 2006-2011 28
  • Figure 18: Acute Pain Therapeutics Market, Germany, Forecast ($m), 2011-2019 29
  • Figure 19: Acute Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011 30
  • Figure 20: Acute Pain Therapeutics Market, Italy, Forecast ($m), 2011-2019 31
  • Figure 21: Acute Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011 32
  • Figure 22: Acute Pain Therapeutics Market, Spain, Forecast ($m), 2011-2019 33
  • Figure 23: Acute Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011 34
  • Figure 24: Acute Pain Therapeutics Market, The UK, Forecast ($m), 2011-2019 35
  • Figure 25: Acute Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011 36
  • Figure 26: Acute Pain Therapeutics Market, Japan, Forecast ($m), 2011-2019 37
  • Figure 27: Opportunity and Unmet Need in the Acute Pain Therapeutics Market, 2011 39
  • Figure 28: Acute Pain Therapeutics, Strategic Competitor Assessment, 2012 42
  • Figure 29: Acute Pain Therapeutics, Pipeline by Phase of Development, 2012 58
  • Figure 30: Acute Pain Therapeutics, Technology Trends Analytics Framework, 2012 61
  • Figure 31: Acute Pain Therapeutics, Technology Trends Analytics Framework - Description, 2012 62
  • Figure 32: Acute Pain Therapeutics, Pipeline by Mechanism of Action, 2012 63
  • Figure 33: Acute Pain Therapeutics Market, Clinical Trials by Country, 2012 68
  • Figure 34: Acute Pain Therapeutics, Clinical Trials by Phase, 2012 69
  • Figure 35: Acute Pain Therapeutics, Clinical Trials by Status, 2012 70
  • Figure 36: Acute Pain Therapeutics Market, Overall Sponsors, 2012 71
  • Figure 37: Acute Pain Therapeutics, Prominent Sponsors, 2012 72
  • Figure 38: Acute Pain Therapeutics, Top Companies Participating in Acute Pain Therapeutics Clinical Trials, 2012 73
  • Figure 39: Acute Pain Therapeutics Market, Drivers and Restraints, 2012 74
  • Figure 40: Implications for Future Market Competition in the Acute Pain Market, 2012 74
  • Figure 41: Acute Pain Therapeutics Market, Pipeline by Company, 2012 76
  • Figure 42: GlobalData Market Size Estimation 84
  • Figure 43: GlobalData Market Forecasting Model 86
Show More
Pricing
Not Available
Get Notified
Email me when related reports are published